NRx Pharmaceuticals faces a precarious financial outlook characterized by a structural inability to achieve consistent commercial scale, as evidenced by the reliance on sporadic revenue streams to offset significant operating losses.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 17, 2026 | -$0.44-312.5% vs -$0.11 | $1M-17.2% vs $1M |
Q3 2026 Aug 14, 2026 | -$0.44-312.5% vs -$0.11 | $1M-17.2% vs $1M |
Q2 2026 May 18, 2026 | -$0.04+20.0% vs -$0.05 | $1M-94.5% vs $19M |
Q2 2026 May 15, 2026 | -$0.04+20.0% vs -$0.05 | $1M-94.5% vs $19M |
Company to issue press release before market open; conference call to follow at 8:30 a.m. ET Company to issue press release before market open; conference call to follow at 8:30 a.m. ET
WILMINGTON, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, today announces completion of three Process Validation lots of preservative free Ketamine produced under commercial conditions in anticipation of the November 10 GDUFA (Generic Drug User Fee Amendments) Goal Date. Process Validation1 is the final step in the drug manufacturing process required to demonstrate compliance with FDA Good Manufacturing Practices (GMP).
In advance of November 10, 2026, GDUFA goal date, all requested changes were classified as “MINOR.” NRx was requested to prepare and submit labels with the proprietary name currently under review by FDA.
DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are not deployable in operational military settings.
Benchmark NRXP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for NRx Pharmaceuticals, Inc. (NRXP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.38 | $41.14M | -3.82 | — | -691.81% | — | — | |
| $132.37 | $6.81B | -44.14 | 65.55% | -18.18% | -189.73% | — | |
| $3.74 | $289.79M | 5.75 | -4.9% | 5.26% | 19.64% | 0.45% | |
| $1.13 | $30.04M | -1.89 | 257.14% | — | -81.71% | — | |
| $8.61 | $1.16B | -5.26 | — | — | -212.85% | — | |
| $6.24 | $77.86M | -9.61 | 32.89% | -148.04% | -173.28% | — |
NRx Pharmaceuticals, Inc. (NRXP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
NRx Pharmaceuticals, Inc. (NRXP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 17, 2026·SEC
Aug 7, 2026·SEC
Jul 22, 2026·SEC
Get notified when NRXP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NRx Pharmaceuticals, Inc. (NRXP) stock FAQ — growth, dividends, profitability & financials explained
NRx Pharmaceuticals, Inc. (NRXP) reported $3.4M in revenue over the trailing twelve months. Revenue was $1.2M in fiscal year 2025.
No. NRx Pharmaceuticals, Inc. (NRXP) reported a net loss of $23.5M over the trailing twelve months.
NRx Pharmaceuticals, Inc. (NRXP) had negative free cash flow of $20.7M over the trailing twelve months.
